KR960705809A - HIV 프로테아제 억제제의 프로드러그(Prodrugs of an inhibitor of HIV protease) - Google Patents
HIV 프로테아제 억제제의 프로드러그(Prodrugs of an inhibitor of HIV protease)Info
- Publication number
- KR960705809A KR960705809A KR1019960702721A KR19960702721A KR960705809A KR 960705809 A KR960705809 A KR 960705809A KR 1019960702721 A KR1019960702721 A KR 1019960702721A KR 19960702721 A KR19960702721 A KR 19960702721A KR 960705809 A KR960705809 A KR 960705809A
- Authority
- KR
- South Korea
- Prior art keywords
- treatment
- hiv
- prodrug
- alkyl
- infection
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
아래 일반식(I)의 프로드러그는 다른 항균제, 면역 조절제, 항생제 또는 백신과의 배합과는 무관하게 희석제 중의 화합물, 약제학적으로 허용가능한 염, 약제학적 조성물 중의 한 형태로서 HIV 프로테아제 억제, HIV에 의한 감염의 예방 또는 치료 및 AIDS 치료에 유용하다. AIDS 의 치료 방법 및 HIV 에 의한 감염의 예방 또는 치료 방법이 또한 기술된다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (8)
- 아래 일반식의 프로드러그 또는 약제학적으로 허용 가능한 이의 염.상기 식에서, Y 및 Z는 모두 H가 아니며, 독립적으로 (a) H; (b); (c)(단, Z는알킬-NH2가 아니다) 또는 (d)이며; n 은 0 내지 16이고; R1및 R2는 독립적으로 H ; 하이드록시; 아미노; 페닐; 헤테로사이클; 또는 치환되지 않거나 하이드록시, -COOH, 아미노, 아릴, 케토 또는 헤테로사이클에 의해 치환된 C1-4알킬이며; R3은 H; 또는 치환되지 않거나 아릴, 아미노, -COOH, 케토,알킬 또는알킬에 의해 치환된 C1-4알킬이고; R4는 H, -NR1R2또는 헤테로사이클이다.
- 제1항에 있어서, 케토코나졸과 배합된 프로드러그.
- 제1항에 있어서, 시메티딘과 배합된 프로드러그.
- 제1항에 있어서, 약제학적으로 허용가능한 염이, Y및 Z중의 하나 이상이 숙시네이트, 글루타레이트 또는 아디페이트 에스테르를 형성하도록, 나트륨, 칼륨, 하이드로클로라이드 또는 설페이트 염인 프로드로그.
- HIV 프로테아제 억제를 요하는 포유동물에게 제1항의 프로드러그 유효량을 투여함을 포함하여, HIV 프로테아제를 억제하는 방법.
- HIV 감염의 예방 또는 HIV에 의한 감염의 치료 또는 AIDS 또는 ARC의 치료를 요하는 포유동물에게 제1항의 프로드로그 유효량을 투여함을 포함하는, HIV 감염의 예방 또는 HIV 에 의한 감염의 치료 또는 AIDS 또는 ARC의 치료 방법.
- 제1항의 프로드러그 유효량과 약제학적으로 허용가능한 담체를 포함하는, HIV 프로테아제 억제에 유용한 약제학적 조성물.
- 제1항의 프로드러그 유효량과 약제학적으로 허용가능한 담체를 포함하는, HIV 감염의 예방 또는 치료 또는 AIDS 또는 ARC 치료에 유용한 약제학적 조성물.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15420493A | 1993-11-18 | 1993-11-18 | |
US08/154,204 | 1993-11-18 | ||
PCT/US1994/013085 WO1995014016A1 (en) | 1993-11-18 | 1994-11-14 | Prodrugs of an inhibitor of hiv protease |
Publications (1)
Publication Number | Publication Date |
---|---|
KR960705809A true KR960705809A (ko) | 1996-11-08 |
Family
ID=22550424
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019960702721A KR960705809A (ko) | 1993-11-18 | 1994-11-14 | HIV 프로테아제 억제제의 프로드러그(Prodrugs of an inhibitor of HIV protease) |
Country Status (17)
Country | Link |
---|---|
US (1) | US5733907A (ko) |
EP (1) | EP0729467A1 (ko) |
JP (1) | JPH09505303A (ko) |
KR (1) | KR960705809A (ko) |
CN (1) | CN1139432A (ko) |
AU (1) | AU687128B2 (ko) |
CA (1) | CA2174649A1 (ko) |
CZ (1) | CZ140696A3 (ko) |
FI (1) | FI962073A0 (ko) |
HU (1) | HUT76270A (ko) |
IL (1) | IL111584A0 (ko) |
NO (1) | NO962000D0 (ko) |
NZ (1) | NZ276622A (ko) |
PL (1) | PL314486A1 (ko) |
SK (1) | SK61496A3 (ko) |
WO (1) | WO1995014016A1 (ko) |
ZA (1) | ZA949127B (ko) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6458772B1 (en) | 1909-10-07 | 2002-10-01 | Medivir Ab | Prodrugs |
US6878728B1 (en) | 1999-06-11 | 2005-04-12 | Vertex Pharmaceutical Incorporated | Inhibitors of aspartyl protease |
US20040122000A1 (en) | 1981-01-07 | 2004-06-24 | Vertex Pharmaceuticals Incorporated. | Inhibitors of aspartyl protease |
MY126358A (en) * | 1996-03-22 | 2006-09-29 | Glaxo Group Ltd | Compositions comprising vx478 and a water soluble tocopherol derivative such as vitamin e-tpgs |
AU2012199A (en) * | 1997-12-24 | 1999-07-19 | Vertex Pharmaceuticals Incorporated | Prodrugs of aspartyl protease inhibitors |
US6436989B1 (en) | 1997-12-24 | 2002-08-20 | Vertex Pharmaceuticals, Incorporated | Prodrugs of aspartyl protease inhibitors |
FR2773994B1 (fr) * | 1998-01-23 | 2002-10-11 | Univ Nice Sophia Antipolis | Prodrogues issues d'anti-proteases inhibitrices du virus de l'immunodeficience humaine (vih) pour l'amelioration de leur biodisponibilite, de leur tropisme vers et/ou de leur delivrance dans le systeme nerveux central |
EP1086076B1 (en) | 1998-06-19 | 2004-12-22 | Vertex Pharmaceuticals Incorporated | Sulfonamide inhibitors of aspartyl protease |
TWI260322B (en) | 1999-02-12 | 2006-08-21 | Vertex Pharma | Inhibitors of aspartyl protease |
CN1441790A (zh) * | 2000-01-28 | 2003-09-10 | 罗姆和哈斯公司 | 增强性质的药物 |
US6818787B2 (en) | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
US7202092B2 (en) * | 2001-07-13 | 2007-04-10 | Roche Diagnostics Operations, Inc. | Indinavir derivatives useful in immunoassay |
EP1485082A4 (en) | 2002-02-19 | 2009-12-30 | Xenoport Inc | PROCESS FOR THE SYNTHESIS OF PROMEDICAMENTS FROM 1-ACYL-ALKYL DERIVATIVES AND CORRESPONDING COMPOSITIONS |
US8603949B2 (en) * | 2003-06-17 | 2013-12-10 | California Institute Of Technology | Libraries of optimized cytochrome P450 enzymes and the optimized P450 enzymes |
US7662987B2 (en) * | 2003-07-15 | 2010-02-16 | Xenoport, Inc. | Methods for synthesis of acyloxyalkyl compounds |
WO2005019163A2 (en) * | 2003-08-20 | 2005-03-03 | Xenoport, Inc. | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use |
EP2371815A1 (en) | 2003-12-30 | 2011-10-05 | XenoPort, Inc. | Sythesis of acyloxyalkyl carbamate prodrugs and intermediates thereof |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US541168A (en) * | 1895-06-18 | Frank e | ||
GB1338169A (en) * | 1971-03-09 | 1973-11-21 | Smith Kline French Lab | Ureas thioureas and guanidines |
US4144346A (en) * | 1977-01-31 | 1979-03-13 | Janssen Pharmaceutica N.V. | Novel 1-(1,3-dioxolan-2-ylmethyl)-1H-imidazoles |
US4661473A (en) * | 1984-03-27 | 1987-04-28 | Merck & Co., Inc. | Renin inhibitors containing peptide isosteres |
WO1989003842A1 (en) * | 1987-10-21 | 1989-05-05 | The Upjohn Company | Renin inhibitors containing a (1-amino-2-hydroxy-2-heterocyclic) ethyl moiety |
DK24089D0 (da) * | 1989-01-20 | 1989-01-20 | Hans Bundgaard | Novel prodrug derivatives of biologically active agents containing hydroxyl groups or nh-acidic groups |
US5218114A (en) * | 1991-04-10 | 1993-06-08 | Merck & Co., Inc. | Cholecystokinin antagonists |
US5169952A (en) * | 1991-07-02 | 1992-12-08 | Merck & Co., Inc. | Stereoselective production of hydroxyamide compounds from chiral α-amino epoxides |
SG52731A1 (en) * | 1991-11-08 | 1998-09-28 | Merck & Co Inc | Hiv protease inhibitors useful for the treatment of aids |
US5413999A (en) * | 1991-11-08 | 1995-05-09 | Merck & Co., Inc. | HIV protease inhibitors useful for the treatment of AIDS |
WO1995002584A2 (en) * | 1993-07-16 | 1995-01-26 | Merck & Co., Inc. | Process for making hiv protease inhibitors |
US5463067A (en) * | 1993-07-16 | 1995-10-31 | Merck & Co., Inc. | Process for making HIV protease inhibitors |
WO1995010281A1 (en) * | 1993-10-13 | 1995-04-20 | Merck & Co., Inc. | Combination therapy for hiv infection |
US5455351A (en) * | 1993-12-13 | 1995-10-03 | Abbott Laboratories | Retroviral protease inhibiting piperazine compounds |
-
1994
- 1994-11-10 IL IL11158494A patent/IL111584A0/xx unknown
- 1994-11-14 HU HU9601340A patent/HUT76270A/hu unknown
- 1994-11-14 KR KR1019960702721A patent/KR960705809A/ko not_active Application Discontinuation
- 1994-11-14 JP JP7514536A patent/JPH09505303A/ja active Pending
- 1994-11-14 CN CN94194700A patent/CN1139432A/zh active Pending
- 1994-11-14 EP EP95901884A patent/EP0729467A1/en not_active Withdrawn
- 1994-11-14 WO PCT/US1994/013085 patent/WO1995014016A1/en not_active Application Discontinuation
- 1994-11-14 SK SK614-96A patent/SK61496A3/sk unknown
- 1994-11-14 CA CA002174649A patent/CA2174649A1/en not_active Abandoned
- 1994-11-14 NZ NZ276622A patent/NZ276622A/en unknown
- 1994-11-14 AU AU10960/95A patent/AU687128B2/en not_active Expired - Fee Related
- 1994-11-14 CZ CZ961406A patent/CZ140696A3/cs unknown
- 1994-11-14 PL PL94314486A patent/PL314486A1/xx unknown
- 1994-11-17 ZA ZA949127A patent/ZA949127B/xx unknown
-
1996
- 1996-03-27 US US08/622,945 patent/US5733907A/en not_active Expired - Fee Related
- 1996-05-15 NO NO962000A patent/NO962000D0/no unknown
- 1996-05-15 FI FI962073A patent/FI962073A0/fi unknown
Also Published As
Publication number | Publication date |
---|---|
FI962073A (fi) | 1996-05-15 |
JPH09505303A (ja) | 1997-05-27 |
NZ276622A (en) | 1997-09-22 |
FI962073A0 (fi) | 1996-05-15 |
ZA949127B (en) | 1996-05-17 |
HU9601340D0 (en) | 1996-07-29 |
IL111584A0 (en) | 1995-01-24 |
EP0729467A1 (en) | 1996-09-04 |
NO962000L (no) | 1996-05-15 |
CZ140696A3 (en) | 1996-12-11 |
PL314486A1 (en) | 1996-09-16 |
CA2174649A1 (en) | 1995-05-26 |
WO1995014016A1 (en) | 1995-05-26 |
NO962000D0 (no) | 1996-05-15 |
AU687128B2 (en) | 1998-02-19 |
AU1096095A (en) | 1995-06-06 |
SK61496A3 (en) | 1996-11-06 |
US5733907A (en) | 1998-03-31 |
HUT76270A (en) | 1997-07-28 |
CN1139432A (zh) | 1997-01-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR960705809A (ko) | HIV 프로테아제 억제제의 프로드러그(Prodrugs of an inhibitor of HIV protease) | |
DK0715623T3 (da) | Blodpladeaggregationsinhibitorer | |
FI954609A (fi) | 1-amidinofenyyli-pyrrolidoneja, -piperidinoneja ja -atsetinoneja verihiutaleiden kasaantumisen inhibiittoreina | |
KR950010888A (ko) | 평활근세포 증식 및 재발협착증을 억제하는 방법 | |
ATE223419T1 (de) | Kondensierte thiadiazolderivate, verfahren zu ihrer herstellung und deren verwendung | |
KR950010892A (ko) | 자궁 섬유증 억제 방법 | |
ES8401927A1 (es) | Procedimiento de obtencion de composiciones oftalmologicas. | |
DK0659193T3 (da) | Blodpladeaggregationsinhibitorer | |
EA199900374A1 (ru) | Ингибитор вторичной катаракты | |
KR950016733A (ko) | 난소 발육부전, 사춘기 지연, 또는 성적 유치증의 억제방법 | |
KR920701240A (ko) | 글루타티온 유도체 | |
ATE186642T1 (de) | Interleukin-1 inhibitor | |
YU6396A (sh) | Kombinacija inhibitora hiv proteaze sa drugim jedinjenjima za terapiju hiv infekcija | |
ES8405358A1 (es) | Procedimiento de obtencion de agentes de beta bloqueantes conteniendo grupos de ester con propiedades oftalmologicas. | |
KR920019767A (ko) | 티아졸 유도체 | |
KR950016736A (ko) | 남성 불임증의 억제 방법 | |
DE68927286T2 (de) | Pyrrolidin-Derivate | |
KR940005541A (ko) | 치환된 벤조에이트 유도체 | |
KR970704441A (ko) | 사람 면역결핍증 바이러스 프로테아제 억제제 배합물(HIV Protease inhibitor combination) | |
KR920000747A (ko) | Hiv역전사효소의 억제제 | |
KR900002787A (ko) | 인체 후천성 면역부전증후군 바이러스 감염 저해제 | |
KR960701088A (ko) | 포스포노메틸디펩타이드(Phosphonomethyldipeptides) | |
KR970703770A (ko) | 사람 면역결핍 바이러스 감염에 대한 배합 치료(Combination therapy for HIV infection) | |
KR960037045A (ko) | B형 바이러스(hbv)성 간염의 예방 및 치료용 약학적 제제 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |